Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant yeast hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant yeast hepatitis B vaccine is a prophylactic vaccine designed to prevent infection by the hepatitis B virus (HBV). It is produced using recombinant DNA technology in yeast expression systems such as Saccharomyces cerevisiae (baker's yeast) or Hansenula polymorpha. The active ingredient is the purified hepatitis B surface antigen (HBsAg), which stimulates an immune response leading to the production of protective antibodies against HBV. This vaccine does not contain live virus or human blood products, eliminating risks associated with earlier plasma-derived vaccines. It is indicated for all individuals at risk of HBV infection, including newborns—especially those born to HBsAg-positive mothers—healthcare workers, and others exposed to blood or body fluids[1][2][3][5]. The mechanism of action involves induction of humoral immunity via anti-HBs antibody production.
- Brand names
- 安在时
- Other names
- 重组酵母乙肝疫苗重组乙型肝炎疫苗（酿酒酵母）重组乙型肝炎疫苗（汉逊酵母）recombinant yeast hepatitis B vaccineyeast-derived hepatitis B vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on recombinant yeast hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant yeast hepatitis B vaccine.